Make informed decisions. Try the FT.
Add this topic to your myFT Digest for news straight to your inbox
M&A buoyed by economic optimism in spite of more cautious Chinese activity
Pharma group valued at SFr1.5bn despite no significant revenues expected for 3 years
Google’s magic number, Bernie off pole position, healthcare megadeal, LME and RBS
Questions asked about price paid for Swiss group and spin-off of promising new drugs
Founder Jean-Paul Clozel to head up standalone spin-off research company
Deal has the untidy look that can result from late concessions
Lack of ambition or exercise in prudence?
Paying too much can lead to high blood pressure
Drug groups renew negotiations one week after discussions broke down
US healthcare group fails to complete major deal for second time in two years
J&J takes away Christmas for shareholders
Biotech company chief’s science background comes into play in face of J&J bid
Structured transaction would see Swiss company remain independent